A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Applied Radiation and Isotopes
Abstract
This work analysed the influence of the chelating group and radioligand on somatostatin analogues in
vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled
analogue with similar blood kinetics and biodistribution to 177Lu-DOTATATE and with lower abdominal
uptake than 131I-TATE. In addition, 131I-DOTATATE showed significative tumour uptake, despite not so
persistent after 24 h. 131I-DOTATATE can represent a cost-effective alternative to lutetium labeled
peptide for neuroendocrine tumours therapy.
Description
p. 227–233.: il p&b. e color.
Citation
ARAÚJO, Elaine Bortoleti de et al. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Applied Radiation and Isotopes, v. 67, p. 227–233, 2009.